Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017

Eurosurveillance

Volumn 22, Issue 6, 2017, Pages

  Skowronski, Danuta M ^a,b   Chambers, C ^a   Sabaiduc, S ^a   Dickinson, J A ^c   Winter, A ^d   De Serres, G ^e,f,g   Drews, S J ^h,i   Jassem, A ^a,b   Gubbay, J B ^d,j   Charest, H ^e   Balshaw, R ^a,b   Bastien, N ^k   Li, Y ^k   Krajden, M ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d PUBLIC HEALTH ONTARIO   (Canada)

^e INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h Prov Laboratory of Northern Alberta   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k PUBLIC HEALTH AGENCY OF CANADA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CELL HETEROGENEITY; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; EPIDEMIC; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; INFLUENZA A (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; CASE CONTROL STUDY; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; OUTCOME ASSESSMENT; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASON; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CANADA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEASONS; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, DNA; VACCINATION; VACCINE POTENCY; YOUNG ADULT;

EID: 85012993336     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2017.22.6.30460     Document Type: Article

References (28)

1. Public Health Agency of Canada (PHAC). FluWatch report: January 8 to January 14, 2017 (week 2). Ottawa: PHAC; 2017. Available from: http://www.healthycanadians.gc.ca/publications/diseases-conditions-maladies-affections/fluwatch-2016-2017-02-surveillance-influenza/index-eng.php?_ga=1.147496691.591173311.1486470400
2. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):21022. DOI:10.2807/1560-7917.ES2015.20.4.21022 PMID: 25655053
3. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. A perfect storm: Impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-2015 season. Clin Infect Dis. 2016;63(1):21-32. DOI:10.1093/cid/ciw176 PMID: 27025838
4. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605-15. DOI:10.1056/NEJMoa0903810 PMID: 19423869
5. Chen Y, Cui D, Zheng S, Yang S, Tong J, Yang D, et al. Simultaneous detection of influenza A, influenza B, and respiratory syncytial viruses and subtyping of influenza A H3N2 virus and H1N1 (2009) virus by multiplex real-time PCR. J Clin Microbiol. 2011;49(4):1653-6. DOI:10.1128/JCM.02184-10 PMID: 21270233
6. Allplex Respiratory Panel Assay. Seoul: Seegene. Available from: http://seegene.com/neo/en/products/respiratory/allplex_Rp_fp.php
7. NxTAG Respiratory Pathogen Panel (RUO). Luminex. Available from: https://www.luminexcorp.com/clinical/ruo-products/nxtag-respiratory-pathogen-panel/
8. Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci USA. 2009;106(21):8701-6. DOI:10.1073/pnas.0903427106 PMID: 19439657
9. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9. DOI:10.1126/science.1244730 PMID: 24264991
10. Public Health Agency of Canada (PHAC). FluWatch report: August 14 to August 27, 2016 (weeks 33-34). Ottawa: PHAC; 2016. Available from: https://www.canada.ca/en/publichealth/services/publications/diseases-conditions/fluwatchreport-august-14-27-2016-weeks-33-34.html
11. Public Health Agency of Canada (PHAC). FluWatch report: August 16 to August 29, 2015 (weeks 33 & 34). Ottawa: PHAC; 2015. Available from: https://www.canada.ca/en/publichealth/services/publications/diseases-conditions/fluwatchreport-august-16-29-2015-weeks-33-34.html
12. Public Health Agency of Canada (PHAC). FluWatch report: August 11 to August 24, 2013 (weeks 33 & 34). Ottawa: PHAC; 2013. Available from: http://publications.gc.ca/collections/collection_2013/aspc-phac/HP58-1-2013-34-eng.pdf
13. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of testnegative design studies. Lancet Infect Dis. 2016;16(8):942-51. DOI:10.1016/S1473-3099(16)00129-8 PMID: 27061888
14. European Centre for Disease Prevention and Control (ECDC). Risk assessment of seasonal influenza, EU/EEA, 2016-2017: Update, 25 January 2017. Stockholm: ECDC; 2017. Available from: http://ecdc.europa.eu/en/publications/Publications/Risk-assessment-seasonal-influenza-2016-2017-update.pdf
15. Schanzer DL, Sevenhuysen C, Winchester B, Mersereau T. Estimating influenza deaths in Canada, 1992-2009. PLoS One. 2013;8(11):e80481. DOI:10.1371/journal.pone.0080481 PMID: 24312225
16. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-86. DOI:10.1001/jama.289.2.179 PMID: 12517228
17. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA. 1999;96(24):14001-6. DOI:10.1073/pnas.96.24.14001 PMID: 10570188
18. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season. Geneva: WHO; 2016. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2016_17_north/en/
19. The Francis Crick Institute. September 2016 interim report. London: The Crick Worldwide Influenza Centre (WIC); 2016. Available from: https://www.crick.ac.uk/media/326439/september_2016_interim_report.pdf
20. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, summary Europe, September 2016. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-viruscharacterisation-september-2016.pdf
21. Neher RA, Bedford T. Nextflu: real-time tracking of seasonal influenza virus evolution in humans. Bioinformatics. 2015;31(21):3546-8. Available from: http://nextflu.org/ h3n2/3y/DOI:10.1093/bioinformatics/btv381 PMID: 26115986
22. Skowronski DM, Sabaiduc S, Chambers C, Eshaghi A, Gubbay JB, Krajden M, et al. Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses. Euro Surveill. 2016;21(3):30112. DOI:10.2807/1560-7917.ES.2016.21.3.30112 PMID: 26836031
23. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One. 2012;7(7):e41895. DOI:10.1371/journal.pone.0041895 PMID: 22848649
24. Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Muraki Y, Hongo S. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J Virol. 2004;78(18):9605-11. DOI:10.1128/JVI.78.18.9605-9611.2004 PMID: 15331693
25. Tate MD, Job ER, Deng Y-M, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294-316. DOI:10.3390/v6031294 PMID: 24638204
26. An Y, McCullers JA, Alymova I, Parsons LM, Cipollo JF. Glycosylation analysis of engineered H3N2 influenza A virus hemagglutinins with sequentially added historically relevant glycosylation sites. J Proteome Res. 2015;14(9):3957-69. DOI:10.1021/acs.jproteome.5b00416 PMID: 26202417
27. Leung VK, Cowling BJ, Feng S, Sullivan SG. Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review. Euro Surveill. 2016;21(16):30202. DOI:10.2807/1560-7917.ES.2016.21.16.30202 PMID: 27124573
28. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol. 2007;36(3):623-31. DOI:10.1093/ije/dym021 PMID: 17403908